Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
Abstract Background PD(L)1 antibodies (anti‐PD(L)‐1) have been a major breakthrough in several types of cancer. Novel patterns of response and progression have been described with anti‐PD(L)‐1. We aimed at characterizing pseudoprogression (PSPD) among patients with various solid tumor types treated...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-04-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2797 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849339217402920960 |
|---|---|
| author | Patricia Martin‐Romano Eduardo Castanon Samy Ammari Stéphane Champiat Antoine Hollebecque Sophie Postel‐Vinay Capucine Baldini Andrea Varga Jean Marie Michot Perrine Vuagnat Aurélien Marabelle Jean‐Charles Soria Charles Ferté Christophe Massard |
| author_facet | Patricia Martin‐Romano Eduardo Castanon Samy Ammari Stéphane Champiat Antoine Hollebecque Sophie Postel‐Vinay Capucine Baldini Andrea Varga Jean Marie Michot Perrine Vuagnat Aurélien Marabelle Jean‐Charles Soria Charles Ferté Christophe Massard |
| author_sort | Patricia Martin‐Romano |
| collection | DOAJ |
| description | Abstract Background PD(L)1 antibodies (anti‐PD(L)‐1) have been a major breakthrough in several types of cancer. Novel patterns of response and progression have been described with anti‐PD(L)‐1. We aimed at characterizing pseudoprogression (PSPD) among patients with various solid tumor types treated by anti‐PD(L)‐1. Methods All consecutive patients (pts) enrolled in phase 1 trials with advanced solid tumors and lymphomas treated in phase I clinical trials evaluating monotherapy by anti‐PD(L)‐1 at Gustave Roussy were analyzed. We aimed to assess prevalence and outcome of PSPD across tumor types. We also intended to describe potential clinical and pathological factors associated with PSPD. Results A total of 169 patients treated with anti‐PD(L)‐1 were included in the study. Most frequent tumor types included melanoma (n = 57) and non‐small cell lung cancer (n = 19). At first tumor evaluation 77 patients (46%) presented with immune unconfirmed progressive disease. Six patients (8%) experienced PSPD: 2 patients with partial response; 4 patients with stable disease. Increase in target lesions in the first CT‐scan was more frequently associated to PSPD (67% vs 33%; P = .04). Patients with a PSPD had a superior survival when compared to patients progressing (median OS: 10.7 months vs 8.7 months; P = .07). Conclusions A small subset of PSPD patients may experience response after an initial progression. Assessment of the current strategy for immune‐related response evaluations may require further attention. |
| format | Article |
| id | doaj-art-a4e7a1041c934bc3942c24fc39614624 |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2020-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-a4e7a1041c934bc3942c24fc396146242025-08-20T03:44:11ZengWileyCancer Medicine2045-76342020-04-01982643265210.1002/cam4.2797Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor typesPatricia Martin‐Romano0Eduardo Castanon1Samy Ammari2Stéphane Champiat3Antoine Hollebecque4Sophie Postel‐Vinay5Capucine Baldini6Andrea Varga7Jean Marie Michot8Perrine Vuagnat9Aurélien Marabelle10Jean‐Charles Soria11Charles Ferté12Christophe Massard13Drug Development Department (DITEP) Gustave Roussy Saclay University of Paris Villejuif FranceOncology Department Clínica Universidad de Navarra Madrid SpainDrug Development Department (DITEP) Gustave Roussy Saclay University of Paris Villejuif FranceDrug Development Department (DITEP) Gustave Roussy Saclay University of Paris Villejuif FranceDrug Development Department (DITEP) Gustave Roussy Saclay University of Paris Villejuif FranceDrug Development Department (DITEP) Gustave Roussy Saclay University of Paris Villejuif FranceDrug Development Department (DITEP) Gustave Roussy Saclay University of Paris Villejuif FranceDrug Development Department (DITEP) Gustave Roussy Saclay University of Paris Villejuif FranceDrug Development Department (DITEP) Gustave Roussy Saclay University of Paris Villejuif FranceDrug Development Department (DITEP) Gustave Roussy Saclay University of Paris Villejuif FranceDrug Development Department (DITEP) Gustave Roussy Saclay University of Paris Villejuif FranceDrug Development Department (DITEP) Gustave Roussy Saclay University of Paris Villejuif FranceDrug Development Department (DITEP) Gustave Roussy Saclay University of Paris Villejuif FranceDrug Development Department (DITEP) Gustave Roussy Saclay University of Paris Villejuif FranceAbstract Background PD(L)1 antibodies (anti‐PD(L)‐1) have been a major breakthrough in several types of cancer. Novel patterns of response and progression have been described with anti‐PD(L)‐1. We aimed at characterizing pseudoprogression (PSPD) among patients with various solid tumor types treated by anti‐PD(L)‐1. Methods All consecutive patients (pts) enrolled in phase 1 trials with advanced solid tumors and lymphomas treated in phase I clinical trials evaluating monotherapy by anti‐PD(L)‐1 at Gustave Roussy were analyzed. We aimed to assess prevalence and outcome of PSPD across tumor types. We also intended to describe potential clinical and pathological factors associated with PSPD. Results A total of 169 patients treated with anti‐PD(L)‐1 were included in the study. Most frequent tumor types included melanoma (n = 57) and non‐small cell lung cancer (n = 19). At first tumor evaluation 77 patients (46%) presented with immune unconfirmed progressive disease. Six patients (8%) experienced PSPD: 2 patients with partial response; 4 patients with stable disease. Increase in target lesions in the first CT‐scan was more frequently associated to PSPD (67% vs 33%; P = .04). Patients with a PSPD had a superior survival when compared to patients progressing (median OS: 10.7 months vs 8.7 months; P = .07). Conclusions A small subset of PSPD patients may experience response after an initial progression. Assessment of the current strategy for immune‐related response evaluations may require further attention.https://doi.org/10.1002/cam4.2797Immune checkpoint inhibitorpseudoprogressionresponse evaluation criteria in solid tumorstreatment beyond progression |
| spellingShingle | Patricia Martin‐Romano Eduardo Castanon Samy Ammari Stéphane Champiat Antoine Hollebecque Sophie Postel‐Vinay Capucine Baldini Andrea Varga Jean Marie Michot Perrine Vuagnat Aurélien Marabelle Jean‐Charles Soria Charles Ferté Christophe Massard Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types Cancer Medicine Immune checkpoint inhibitor pseudoprogression response evaluation criteria in solid tumors treatment beyond progression |
| title | Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types |
| title_full | Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types |
| title_fullStr | Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types |
| title_full_unstemmed | Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types |
| title_short | Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types |
| title_sort | evidence of pseudoprogression in patients treated with pd1 pdl1 antibodies across tumor types |
| topic | Immune checkpoint inhibitor pseudoprogression response evaluation criteria in solid tumors treatment beyond progression |
| url | https://doi.org/10.1002/cam4.2797 |
| work_keys_str_mv | AT patriciamartinromano evidenceofpseudoprogressioninpatientstreatedwithpd1pdl1antibodiesacrosstumortypes AT eduardocastanon evidenceofpseudoprogressioninpatientstreatedwithpd1pdl1antibodiesacrosstumortypes AT samyammari evidenceofpseudoprogressioninpatientstreatedwithpd1pdl1antibodiesacrosstumortypes AT stephanechampiat evidenceofpseudoprogressioninpatientstreatedwithpd1pdl1antibodiesacrosstumortypes AT antoinehollebecque evidenceofpseudoprogressioninpatientstreatedwithpd1pdl1antibodiesacrosstumortypes AT sophiepostelvinay evidenceofpseudoprogressioninpatientstreatedwithpd1pdl1antibodiesacrosstumortypes AT capucinebaldini evidenceofpseudoprogressioninpatientstreatedwithpd1pdl1antibodiesacrosstumortypes AT andreavarga evidenceofpseudoprogressioninpatientstreatedwithpd1pdl1antibodiesacrosstumortypes AT jeanmariemichot evidenceofpseudoprogressioninpatientstreatedwithpd1pdl1antibodiesacrosstumortypes AT perrinevuagnat evidenceofpseudoprogressioninpatientstreatedwithpd1pdl1antibodiesacrosstumortypes AT aurelienmarabelle evidenceofpseudoprogressioninpatientstreatedwithpd1pdl1antibodiesacrosstumortypes AT jeancharlessoria evidenceofpseudoprogressioninpatientstreatedwithpd1pdl1antibodiesacrosstumortypes AT charlesferte evidenceofpseudoprogressioninpatientstreatedwithpd1pdl1antibodiesacrosstumortypes AT christophemassard evidenceofpseudoprogressioninpatientstreatedwithpd1pdl1antibodiesacrosstumortypes |